The information on this web site is being disclosed for the purposes of AIM Rule 26 and was last updated on 20 February 2019.
The main country of operation and country of incorporation is the UK. Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market and is developing a pipeline of immunotherapies for the treatment of cancer based on its patented ImmunoBody® and Moditope® platforms. The Company's mission is to develop therapeutic cancer vaccines that stimulate the patient's immune system to mount an active response to 'reject' or kill the growing tumour.
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
Mon, 20 May 2019 09:51:00
Scancell has a clinical development partnership with Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research
Mon, 20 May 2019 06:23:00
“The initial focus of the board will be to inform the clinical strategy for the planned Modi-1 clinical trial and to ensure the best possible outcome in several solid tumour indications”
Fri, 10 May 2019 05:45:00
Sign up to our newsletter to stay up to date with Scancell